Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioInvent International AB's quarterly market cap
increased
from Sep. 2025 (€164.51 Mil) to Dec. 2025 (€176.68 Mil) but then
declined
from Dec. 2025 (€176.68 Mil) to Mar. 2026 (€131.94 Mil).
BioInvent International AB's annual market cap
increased
from Dec. 2023 (€107.92 Mil) to Dec. 2024 (€218.47 Mil) but then
declined
from Dec. 2024 (€218.47 Mil) to Dec. 2025 (€176.68 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioInvent International AB's Enterprise Value for Today is €93.71 Mil.
BioInvent International AB (STU:BIX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BioInvent International AB Market Cap Related Terms
BioInvent International AB Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:BIX vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, BioInvent International AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's Market Cap distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB (STU:BIX) has a Market Cap of €134.26 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioInvent International AB and its competitors. According to the industry distribution chart, BioInvent International AB ranks #655 out of 1423 companies in the Biotechnology industry, placing it in the top 46%.
Is BioInvent International AB's Market Cap too high?
BioInvent International AB's current Market Cap is €134.26 Mil. Based on the distribution chart, BioInvent International AB ranks #655 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioInvent International AB has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioInvent International AB ranks #655 out of 1423 companies for Market Cap. This puts BioInvent International AB in the upper half of its industry. The industry median Market Cap is 111.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 111.61, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioInvent International AB and its competitors. For the Biotechnology industry, the median Market Cap is 111.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioInvent International AB's current Market Cap is €134.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
Based on GuruFocus' analysis, BioInvent International AB (STU:BIX) is currently considered Possible Value Trap. The stock's GF Value™ is €4.34, compared to a current price of €2.00 — trading 54% below its estimated fair value. The current Market Cap is €134.26 Mil. BioInvent International AB's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BioInvent International AB (STU:BIX), the current Market Cap is €134.26 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (STU:BIX) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued.
The current stock price of €2.00 is trading 54% below its estimated GF Value™ of €4.34.
GuruFocus considers BioInvent International AB to be Possible Value Trap.
Key valuation signals for STU:BIX:
Market Cap: €134.26 Mil
GF Value™: €4.34 vs. price of €2.00 (54% below fair value)
No single metric tells the full story. See the STU:BIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
51GF Score
Get the complete analysis for STU:BIX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:BIX has been successfully added to your 
